OIM
PACB icon

Oracle Investment Management’s Pacific Biosciences PACB Stock Holding History

Oracle Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-279,638
Closed -$512K – 21
2024
Q4 		$512K Sell
279,638
-448,239
-62% -$875K 0.28% 17
2024
Q3 		$1.24M Buy
727,877
+304,739
+72% +$501K 0.74% 16
2024
Q2 		$580K Sell
423,138
-932,888
-69% -$1.88M 0.54% 18
2024
Q1 		$5.09M Sell
1,356,026
-20,769
-2% -$122K 3.38% 9
2023
Q4 		$13.5M Sell
1,376,795
-261,600
-16% -$2.14M 8.21% 4
2023
Q3 		$13.7M Sell
1,638,395
-377,100
-19% -$4.31M 4.2% 6
2023
Q2 		$26.8M Hold
2,015,495
– – 19.75% 1
2023
Q1 		$23.3M Sell
2,015,495
-139,312
-6% -$1.39M 22.59% 1
2022
Q4 		$17.6M Buy
2,154,807
+761,642
+55% +$6.56M 14.7% 2
2022
Q3 		$8.09M Buy
1,393,165
+589,320
+73% +$3.38M 4.59% 6
2022
Q2 		$3.55M Sell
803,845
-421,550
-34% -$2.56M 1.08% 12
2022
Q1 		$11.2M Sell
1,225,395
-195,257
-14% -$2.25M 2.21% 8
2021
Q4 		$29.1M Sell
1,420,652
-24,307
-2% -$587K 4.14% 6
2021
Q3 		$36.9M Buy
1,444,959
+70,800
+5% +$2.1M 4.6% 6
2021
Q2 		$48.1M Sell
1,374,159
-72,300
-5% -$2.1M 6.62% 6
2021
Q1 		$48.2M Sell
1,446,459
-275,000
-16% -$9.63M 7.22% 5
2020
Q4 		$44.7M Hold
1,721,459
– – 5.6% 5
2020
Q3 		$17M Buy
1,721,459
+401,100
+30% +$2.31M 2.24% 7
2020
Q2 		$4.55M Buy
1,320,359
+100,000
+8% +$340K 0.58% 13
2020
Q1 		$3.73M Buy
1,220,359
+109,693
+10% +$449K 1.11% 10
2019
Q4 		$5.71M Hold
1,110,666
– – 1.07% 12
2019
Q3 		$5.73M Hold
1,110,666
– – 1.41% 9
2019
Q2 		$6.72M Hold
1,110,666
– – 1.45% 11
2019
Q1 		$8.03M Sell
1,110,666
-1,447,098
-57% -$10.5M 1.71% 10
2018
Q4 		$18.9M Sell
2,557,764
-6,829,870
-73% -$43.3M 5.87% 5
2018
Q3 		$50.8M Sell
9,387,634
-317,127
-3% -$1.36M 11.12% 4
2018
Q2 		$34.5M Buy
9,704,761
+167,100
+2% +$464K 8.33% 3
2018
Q1 		$19.6M Buy
9,537,661
+1,084,286
+13% +$2.82M 4.74% 4
2017
Q4 		$22.3M Sell
8,453,375
-233,080
-3% -$816K 4.43% 6
2017
Q3 		$45.6M Buy
8,686,455
+427,075
+5% +$1.84M 7.48% 5
2017
Q2 		$29.4M Buy
8,259,380
+2,752,648
+50% +$11.1M 4.65% 6
2017
Q1 		$28.5M Sell
5,506,732
-10,162
-0.2% -$49.7K 4.44% 6
2016
Q4 		$21M Buy
5,516,894
+518,328
+10% +$3.77M 3.48% 8
2016
Q3 		$44.8M Buy
4,998,566
+1,816,297
+57% +$15.2M 6.9% 7
2016
Q2 		$22.4M Sell
3,182,269
-129,820
-4% -$1.19M 5.21% 7
2016
Q1 		$26.6M Sell
3,312,089
-344,342
-9% -$3.39M 6.92% 7
2015
Q4 		$48M Buy
3,656,431
+420,270
+13% +$3.77M 8.32% 4
2015
Q3 		$11.8M Sell
3,236,161
-5,600
-0.2% -$27.4K 2.42% 14
2015
Q2 		$18.7M Sell
3,241,761
-43,035
-1% -$249K 2.27% 15
2015
Q1 		$19.2M Buy
3,284,796
+54,278
+2% +$374K 2.43% 17
2014
Q4 		$25.3M Buy
3,230,518
+5,000
+0.2% +$32K 3.32% 13
2014
Q3 		$15.8M Buy
3,225,518
+223,010
+7% +$1.17M 2.19% 14
2014
Q2 		$18.6M Buy
3,002,508
+426,779
+17% +$2.14M 2.25% 15
2014
Q1 		$13.8M Hold
2,575,729
– – 1.57% 19
2013
Q4 		$13.5M Buy
2,575,729
+614,041
+31% +$2.82M 1.85% 15
2013
Q3 		$10.8M Hold
1,961,688
– – 1.54% 16
2013
Q2 		$4.96M Buy
+1,961,688
New +$4.88M 0.86% 17

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oracle Investment Management's PACB Position: Q1 2025 in Review

Oracle Investment Management sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 279,638 shares — an estimated $512K sold.

Oracle Investment Management first reported a position in PACB in Q2 2013 and held it in 47 quarters. The position peaked at $50.8M in Q3 2018. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

  • Oracle Investment Management reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
  • Oracle Investment Management sold 279,638 Pacific Biosciences shares in Q1 2025, an estimated $512K.
  • Oracle Investment Management first reported a position in Pacific Biosciences in Q2 2013 and held it in 47 quarters.
  • Oracle Investment Management's Pacific Biosciences position peaked at $50.8M in Q3 2018.
  • 225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Oracle Investment Management's 13F filing for Q1 2025, filed 15 May 2025.